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Objective: To investigate the association between long-term weight change and blood metabolites.
Methods: Change in BMI over 8.66 3.79 years was assessed in 3,176 females from the TwinsUK cohort
(age range: 18.3-79.6, baseline BMI: 25.116 4.35) measured for 280 metabolites at follow-up. Statistically
significant metabolites (adjusting for covariates) were included in a multivariable least absolute shrinkage
and selection operator (LASSO) model. Findings were replicated in the Cooperative Health Research in
the Region of Augsburg (KORA) study (n51,760; age range: 25-70, baseline BMI: 27.7264.53). The
study examined whether the metabolites identified could prospectively predict weight change in KORA
and in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) study (n5 471; age range: 55-74,
baseline BMI: 27.246 5.37).
Results: Thirty metabolites were significantly associated with change in BMI per year in TwinsUK using
Bonferroni correction. Four were independently associated with weight change in the multivariable
LASSO model and replicated in KORA: namely, urate (meta-analysis b [95% CI]5 0.05 [0.040 to 0.063];
P5 1.373 10219), gamma-glutamyl valine (b [95% CI]5 0.06 [0.046 to 0.070]; P5 1.233 10220), butyryl-
carnitine (b [95% CI]5 0.04 [0.028 to 0.051]; P5 6.723 10212), and 3-phenylpropionate (b [95%
CI]520.03 [20.041 to 20.019]; P5 9.831028), all involved in oxidative stress. Higher levels of urate at
baseline were associated with weight gain in KORA and PLCO.
Conclusions: Metabolites linked to higher oxidative stress are associated with increased long-term
weight gain.
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Introduction
Obesity is a major public health concern resulting from a positive
energy balance for an extended period of time (1). Although most peo-
ple in industrialized nations have overweight or obesity, significant
numbers of people with normal weight never develop overweight or
obesity, partly reflecting the large interindividual variation in response
to excess caloric intake (1). A clear understanding of the mechanisms
of obesity and development of effective strategies for its prevention
and treatment require consideration of biochemical changes resulting
from weight gain and loss of metabolic homeostasis (2).
Comprehensive metabolic profiling provides an opportunity to gain
new insights into biochemical differences involved in weight loss or
gain in humans. Several metabolomic studies have been carried out to
date, although most of them have focused on the overlap between obe-
sity and type 2 diabetes mellitus (3). Dozens of metabolites fall into
that category, including branched-chain amino acids (BCAAs), cyste-
ine, glutamine, phenylalanine, proline, tyrosine, threonine, tryptophan,
choline, and pantothenic acid, which are increased in both obesity and
diabetes. In contrast, asparagine, glycine, methionine, and citrulline are
decreased in both obesity and diabetes (4). Metabolomic profiling of
BMI and obesity independent of the link with diabetes has also been
performed. In a cross-sectional study of 947 participants, 37 metabo-
lites were significantly associated with BMI, including 19 lipids, 12
amino acids, and 6 others. Eighteen of these associated metabolites had
not been previously reported on, including histidine and butyrylcarni-
tine, a lipid marker of whole-body fatty acid oxidation (5).
Similar results have been derived from smaller studies focused on
child obesity. A study profiling serum samples of 80 children with
obesity and 40 children with normal weight identified 14 metabo-
lites (glutamine, methionine, proline, 9 phospholipids, and 2 acylcar-
nitines) that were significantly different when comparing children
with normal weight and children with obesity (6).
Less research has been conducted to investigate the metabolites
related not to high or low BMI but to change in BMI per year. One
study investigated the metabolic adaptations seen after bariatric sur-
gery. The metabolic footprint of bariatric procedures appears to be
specifically characterized by an increase of bile acid circulating
pools and a decrease of ceramide levels, a greater perioperative
decline in BCAA, and the rise of circulating serine and glycine, mir-
roring glycemic control and inflammation improvement (7).
A recent study from the Cooperative Health Research in the Region
of Augsburg (KORA) cohort defined metabolite modules or clusters
of related molecules (using weighted correlation network) and then
identified four metabolite modules significantly and stably associ-
ated with body weight gain. These included major branches of
metabolism, with very low-density lipoprotein, low-density lipopro-
tein (LDL), and large high-density lipoprotein subclasses, triglycer-
ides, BCAAs, and markers of energy metabolism, among others (8).
However, a key question is “What are the molecular pathways that
are associated with greater or lower weight change over time?” This
is relevant if these factors are to be addressed and eventually modi-
fied for therapeutic purposes.
In this study, we used longitudinal measures of BMI in 3,176 women
from the TwinsUK cohort assessed 8.6 years apart. Having adjusted
for age and BMI at baseline, smoking, and family relatedness, we car-
ried out metabolomic profiling of change in BMI per year. We repli-
cated our results in 1,760 individuals from KORA and in an elderly
cohort from the United States. Having identified metabolites whose
levels are significantly and reproducibly altered by weight change, we
then tested in a subanalysis whether the levels of any of these at base-
line (before weight change) were also associated with weight change.
Methods
Discovery cohort
Study subjects were twins enrolled in the TwinsUK registry, a
national register of adult twins recruited as volunteers without
selecting for any particular disease or trait (9). All recruited twins
were of the same sex. In this study, we analyzed data from 3,176
females (age range: 18.3-79.6) from the TwinsUK cohort with BMI
assessed on average 8.66 3.79 years apart and metabolomic profil-
ing conducted at follow-up.
The study was approved by St Thomas’ Hospital Research Ethics
Committee, and all twins provided informed written consent.
Replication cohorts
The replication cohort consisted of individuals from the follow-up
study (KORA F4) drawn from the general population of the region of
Augsburg, Germany (10). The average follow-up time from the base-
line study (KORA S4) was 7.116 0.22 years. In total, we analyzed
1,760 individuals (age range: 25-70) with fasting serum metabolomic
profiles made available using the Metabolon, Inc. (Durham, North
Carolina) platform and with the measure of longitudinal BMI.
We tested whether the identified and replicated metabolites could
also predict weight change on a different set of fasting and nonfast-
ing samples from the KORA S4 study, which comprised 1,069 sub-
jects (age range: 32-77) with nontargeted metabolomic data at base-
line and longitudinal BMI.
We also included 471 female controls (age range: 55-74) from the
Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) study (11).
Eligibility criteria were that participants had to be controls, had to
have a follow-up weight measurement, and had to have metabolomic
profiling available. For PLCO, metabolomic profiling was available
only at baseline.
The PLCO trial is registered at ClinicalTrials.gov as NCT00002540,
and it was approved by the institutional review boards of the US
National Cancer Institute and the 10 screening centers. Only con-
trols from this trial are included in this study. The KORA F4/S4
study was approved by the ethics committee of the Bavarian Medi-
cal Association.
Assessment of weight gain, weight loss, and
covariates
Height and weight were measured once at baseline and once at
follow-up, which was on average 8.66 3.79 years after the baseline
assessment. BMI was calculated by dividing weight (in kilograms)
by the square of height (in meters).
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For the subanalysis and for computing box plots of the metabolites’
distribution, the change in BMI per year was calculated by adjusting
for age, BMI at baseline, smoking, metabolite batch, and family
relatedness. Subjects were then categorized based on these tertiles.
The weight gain group was defined as the top tertile, while the low
weight gain (weight loss) group was defined as the lower tertile
(12). The middle tertile was excluded from the subanalysis.
Metabolomics measurements
Nontargeted metabolite detection and quantification were conducted
by the metabolomics provider Metabolon on 3,176 fasting samples
from participants in the TwinsUK study, as described previously (13)
(for details, see the Supporting Information). The metabolomic data
set measured by Metabolon includes 280 metabolites of known chem-
ical identity containing the following broad categories: amino acids,
acylcarnitines, sphingomyelins, glycerophospholipids, carbohydrates,
vitamins, lipids, nucleotides, peptides, xenobiotics, and steroids.
Circulating levels of saturated fatty acids (SFAs), total fatty acids
(TotFAs), monounsaturated fatty acids, and polyunsaturated fatty
acids (PUFAs) were measured by Nightingale Health, previously
known as Brainshake Ltd. (Vantaa, Finland; https://nightingale-
health.com/services), from fasting serum samples using proton
nuclear magnetic resonance spectroscopy at 500 MHz and 600
MHz, as previously described (14). Traits were natural log-
transformed and then scaled to standard deviation (SD) units, as pre-
viously proposed by W€urtz et al (15). For the metabolites containing
zeros, one was added to all values of that metabolite before natural
log-transformation.
Statistical analysis
Statistical analysis was carried out using the data analysis and statis-
tical software Stata version 11 (StataCorp LLC, College Station,
Texas) and R version 3.3.1 (R Foundation for Statistical Computing,
Vienna, Austria). We inverse normalized the metabolite data, as the
metabolite concentrations were not normally distributed. We
excluded metabolic traits with more than 20% of values missing.
We imputed individual metabolites not detected in a sample using
the minimum run-day measures.
Linear regression analysis adjusting for age, BMI at baseline, smok-
ing, metabolite batch, and family relatedness was undertaken to
identify associations between biomarkers and weight change. We
corrected for multiple testing using Bonferroni correction
(P< 1.23 1024). To identify a set of metabolites independently
associated with weight change, we fitted the least absolute shrinkage
and selection operator method (LASSO), incorporating all significant
metabolites together with age, smoking, and metabolite batch.
LASSO is a regression method that performs both variable selection
and regularization. It involves penalizing the absolute size of the
regression coefficients with some parameter estimates shrunk to zero
(16). The penalty parameter was chosen as the largest k such that
error is within one standard error of the minimum as determined by
cross validation using the glmnet package in R (17).
Replication analysis
The metabolites independently associated with weight change were
replicated in 1,760 individuals from the KORA cohort. Results were
then combined using an inverse variance fixed-effect meta-analysis.
The fixed-effect model provides a weighted average of the study
estimates, the weights being the inverse of the variance of the study
estimate.
We computed the area under the curve (AUC) and 95% CIs for a
receiver operating characteristic curve comparing the top and bottom
tertiles of BMI change per year in the TwinsUK cohort. Two models
were fitted: (1) demographics and lifestyle, including age, baseline
BMI, and smoking and (2) all variables in (1) plus the inverse nor-
mal concentrations of the four successfully replicated metabolites.
This allowed us to evaluate the extent to which the significant
metabolites contribute to the AUC in addition to the demographic
and lifestyle variables. As metabolites may also be predictive of
BMI change per year, we finally tested the association of weight
change and metabolites at baseline in both KORA and PLCO.
Metabolomic data at baseline in twins were not available.
Results
The descriptive characteristics of the study participants are presented
in Table 1. Thirty metabolites were associated with weight change
after adjusting for covariates and multiple testing using Bonferroni
correction. We investigated whether these associations were sensi-
tive to the various adjustments and found that results were consistent
(Supporting Information Tables S1-S2).
We then used a LASSO model to analyze these 30 metabolites,
identifying 7 that contributed independently to weight change (Table
2). Of those, 4 were successfully replicated in the KORA cohort and
were therefore meta-analyzed using inverse variance fixed-effect
meta-analysis. Urate (meta-analysis b [95% CI]5 0.05 [0.040 to
0.063]; P5 1.373 10219), gamma-glutamyl valine (b [95%
CI]5 0.06 [0.046 to 0.070]; P5 1.233 10220), and butyrylcarnitine
(b [95% CI]5 0.04 [0.028 to 0.051]; P5 6.723 10212) were posi-
tively associated with weight gain, while 3-phenylpropionate (hydro-
cinnamate) (b [95% CI]520.03 [20.041 to 20.019];
P5 9.83 1028 ) was inversely associated with weight change. Sup-
porting Information Figure S1 shows the box plot of the distribution
of the four metabolite concentrations (in the inverse normal scale)
for each of the three tertiles of change in BMI per year. Tertile 1
refers to individuals with the lowest BMI change per year, while ter-
tile 3 refers to the highest BMI gain over time.
TABLE 1 Descriptive characteristics of the study population
TwinsUK KORA PLCO
Females (%) 100 51 100
Age at baseline 50.266 10.24 53.726 8.79 62.656 5.12
Age at follow-up 58.866 10.54 60.826 8.79 71.746 5.89
BMI at baseline 25.116 4.35 27.726 4.53 27.246 5.37
BMI at follow-up 26.386 4.76 28.176 4.81 27.606 5.71
Current smoker (%) 8.09 14.77 5.94
Values represent the mean (SD) unless otherwise specified.
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To quantify how much of the change in BMI per year was explained
by these four metabolites, we computed the AUC in a receiver
operating characteristic analysis. We found that the AUC obtained
by adding these four metabolites was significantly greater than for
the lifestyle and demographic variables alone. Demographics plus
smoking gave an AUC of 0.563 (95% CI: 0.539-0.587), whereas the
addition of the metabolite data resulted in an AUC of 0.637 (95%
CI: 0.614-0.660) (Supporting Information Figure S2).
The full metabolome has been previously investigated for its associa-
tion with intake of 71 food groups (18). (The full information can be
searched online at http://www.twinsuk.ac.uk/dietmetab-data/.) Of the
metabolites identified here as related to weight change, urate, gamma-
glutamyl valine, and butyrylcarnitine were not associated with any of
the 71 food groups that we considered. On the other hand,
3-phenylpropionate (hydrocinnamate), which was associated with neg-
ative BMI change, was associated with higher consumption of apples
and pears (b [SE]5 0.02 [0.004]; P5 1.243 1028) and lower con-
sumption of fried fish (b [SE]520.17 [0.05]; P5 4.123 10211) and
savory pies (b [SE]520.23 [0.04]; P5 3.723 10210) (18).
We further tested whether baseline levels of these metabolites were
also predictive of weight change and found that circulating levels of
urate at baseline were associated with higher weight gain at follow-
up in both KORA (b [SE]5 0.02 [0.009]; P5 0.04) and PLCO
(b [SE]5 0.04 [0.020]; P5 0.008) and in the meta-analysis (b [95%
CI]5 0.023 [0.007-0.039]; P5 0.004).
We hypothesized that urate may be a surrogate marker of the meta-
bolic change or changes that result in weight gain. If this were true,
we would expect levels of urate at baseline to be positively corre-
lated with levels of fatty acids in blood in individuals who gain the
most weight. If that were the case, there should be no such meta-
bolic change in people who lose weight. Given the link to oxidative
stress, we further hypothesized that this might affect SFAs and
PUFAs differently. We therefore tested the interactions between
urate and circulating levels of SFA, TotFA, monounsaturated fatty
acid, and PUFA in the weight gain and weight loss groups (top and
bottom tertiles of the weight change distribution, which had changes
of 20.176 0.26 and 0.396 0.22 kg/m2 per year, respectively) and
found that the association between urate and both SFAs and TotFAs
was only present in those who gained weight (SFA: b [SE]5 0.09
[0.04]; P5 0.04; TotFA: b [SE]5 0.1 [0.04]; P5 0.02), while lower
PUFAs were associated with higher circulating urate levels in
those who lost weight (PUFA: b [SE]520.1 [0.03]; P5 0.002)
(Figure 1).
Discussion
In this study, we profiled the metabolic signatures of long-term
weight change. Having assessed the association between circulating
metabolites and weight change, we identified four metabolites—urate,
butyrylcarnitine, gamma-glutamylvaline and 3-phenylpropionate
(hydrocinnamate), all of which have been previously linked to higher
oxidative stress—that were independently associated with long-term
weight gain and successfully replicated in an independent cohort.
Previous studies reported that several metabolites—including
BCAAs, butyrylcarnitine cysteine, glutamine, phenylalanine, proline,TA
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tyrosine, histidine, threonine, tryptophan, choline, pantothenic acid,
LDL, very low-density lipoprotein, asparagine, glycine, methionine,
and citrulline, among others—were associated with obesity (3-5).
Some of the metabolites we identified as related to weight change
have been previously linked to obesity, specifically butyrylcarnitine,
which was reported by Moore et al. in individuals of both Asian and
European descent (5). We did not find a correlation with BCAAs,
which are well-known markers of visceral fat (19), obesity in gen-
eral (7), and type 2 diabetes (3). Also, unlike the authors of previous
studies (8), we did not find a strong correlation between weight
change and lipids such as LDL or other forms of cholesterol. These
findings are in line with those of studies of high fat and high
sucrose intake with regards to the generation of reactive oxygen spe-
cies (ROS). Treatment with high glucose or high fatty acid concen-
trations in cultured skeletal muscle cells has been shown to induce
ROS production and mitochondrial damage in myotubes (20). In
both rodents and humans, a high-fat diet increased the hydrogen per-
oxide-emitting potential of mitochondria without any changes in oxi-
dative capacity (21). Not only does high-fat, high-sucrose feeding in
mice result in increased ROS production, but this ROS production
also results in mitochondrial dysfunction (20,21). In light of this
finding, a possible mechanism linking the metabolites identified in
our study and previous research could be the strong link between a
dysfunction in energy metabolism and ROS generation.
Butyrylcarnitine
Butyrylcarnitine is an acylcarnitine, a type of compound derived
from mitochondrial acyl-CoA metabolism, and it has been associated
with diet-induced insulin resistance (22). Acylcarnitines comprise an
acyl group esterified to L-carnitine, which enables them to cross the
mitochondrial membrane. Several recent studies show increased lev-
els of multiple acylcarnitines in subjects with obesity and insulin
resistance (23). Acylcarnitines are generated during incomplete fatty
acid beta-oxidation, and treatment of cultured murine and human
myotubes with these compounds induces insulin resistance and oxi-
dative stress (24). High levels of butyrylcarnitine are therefore indic-
ative of incomplete beta-oxidation and are likely causative of
increased ROS.
Gamma-glutamylvaline
Gamma-glutamylvaline, like other gamma-glutamylated amino acids,
is an established marker of oxidative stress and reflective of gluta-
thione (GSH) turnover (25). GSH is the major redox buffer in the
cell (26). It protects cellular components from oxidative damage of
ROS such as hydrogen peroxide and organic peroxides via GSH per-
oxidases and also detoxifies the electrophilic metabolites of toxins
(27). The intracellular redox environment can be measured through
Figure 1 Association between circulating urate and fatty acids among participants with weight gain and those
with weight loss. Linear regression coefficient b values (95% CIs) are depicted.
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the redox state of the GSH disulfide/GSH couple (28). Under condi-
tions of oxidative stress, intracellular GSH turnover is increased,
activating the enzyme c-glutamyl transpeptidase to cleave extracellu-
lar GSH to release gamma-glutamylated amino acids, which are
taken up for intracellular GSH reconstitution. A drop in such amino
acids has been reported in response to vitamin E treatment (25).
3-phenylpropionate (hydrocinnamate)
Lower levels of the metabolite 3-phenylpropionate (hydrocinnamate)
were also reproducibly associated with weight gain. Hydrocinnamate
is a phenolic compound (29) with well-characterized antioxidant
activity (30). Moreover, derivatives of this compound are known to
have agonistic effects on peroxisome proliferator-activated receptors
with antidiabetic and lipid-lowering activity (31).
Urate
In humans, the final compound of purine catabolism is uric acid
(32). Urate is a well-known marker of intracellular prooxidant and
inflammatory status. Although it has antioxidant activity extracellu-
larly, it has been widely linked to increased risk of metabolic syn-
drome (33). We found urate to be associated with weight change in
all cohorts (Table 2), with urate levels at baseline being correlated
with higher weight gain at follow-up.
Urate, despite being a major antioxidant in the human plasma, both
correlates and predicts development of obesity, hypertension, and
cardiovascular disease, conditions associated with oxidative stress
(34). Urate is a prooxidant when forming radicals in reactions with
other oxidants, and these radicals predominantly target lipids (LDL
and membranes) rather than other cellular components. However,
the hydrophobic environment created by lipids is unfavorable for the
antioxidant effects of uric acid, and oxidized lipids thus convert uric
acid into an oxidant (34). There is a substantial body of evidence
indicating that uric acid has a direct effect on adipose tissue, and
this effect has a redox-dependent component (34-36). Moreover,
hyperuricemia was previously found to be a mediator linking obesity
with kidney disease and might, thus, increase oxidative stress due to
decreasing renal function (37).
Proposed biological mechanism
The metabolic signatures we saw therefore could be interpreted as
follows: The increase in fatty acids and carbohydrates produces
increased ROS (as witnessed by the accumulation of gamma glu-
tamyl amino acids) and incomplete beta-oxidation (accumulation of
acylcarnitines), which in turn causes mitochondrial dysfunction
linked to a dysregulation of the tricarboxylic acid cycle. This would
result in decreased adenosine triphosphate production, and eventu-
ally mitochondrial DNA degradation, leading to the release of nucle-
otides, nucleosides, and nucleobases, which are metabolized to urate
by oxidation.
In a subanalysis of TwinsUK cohort data we found that urate is cor-
related with increased levels of SFAs and TotFAs, but only in indi-
viduals who gain weight (Figure 1). On the other hand, PUFAs,
which have an antioxidant effect themselves (38), are correlated
with lower levels of urate, but only in individuals who lose weight.
Our data therefore suggest that increases (even at normal levels) of
urate may potentially be markers of the start of metabolic changes
that result in long-term weight gain. It also suggests that the metabo-
lites identified in our study might be used to monitor the efficacy of
therapies aimed at restoring mitochondrial function, such as ongoing
clinical trials using nicotinamide adenine dinucleotide precursors (39).
Urate is not only an easily measured marker that can be monitored in
therapies aimed at reducing weight gain, but, importantly, may also
be modified through the use of urate-lowering therapy. We note, how-
ever, that this is merely one interpretation of the data, and we were
unable to prove causality; therefore, other interpretations are possible.
The current study has several strengths. It used a nontargeted metabo-
lomics approach that identified a wide range of biochemicals in addi-
tion to lipids. TwinsUK is a very large and extensively phenotyped
cohort, and we replicated our results in two independent cohorts.
We also note several study limitations. Our discovery sample con-
sisted of females only. Longitudinal metabolomic data were not
available in all of the three cohorts. Also, we did not have a direct
measure of oxidative phosphorylation and redox function in these
subjects. The lack of metabolomic data at baseline in the discovery
cohort did not allow us to test the predictive value of these metabo-
lites on weight loss or gain.
Another important limitation is the possibility of confounding with
total energy intake and expenditure. Adjustment using self-reported
measures from questionnaires on diet and physical activity did not
make a difference to our findings, but these self-report values are
not objectively measured, are subject to bias, and have wide margins
of error (40,41). In this study, we were unable to adjust for objective
measures of energy intake and expenditure, and therefore, the effects
that we reported may be affected if adjusted by such measures. On
the other hand, the four metabolites that we focused on were repli-
cated in two independent studies, lending further confidence to the
robustness of the four metabolomic associations reported here.
In conclusion, our study shows that metabolites linked to higher oxi-
dative stress define a metabolic profile correlated with long-term
weight gain and that urate at baseline is associated with weight gain
over time.O
VC 2017 The Authors. Obesity published by Wiley Periodicals, Inc. on
behalf of The Obesity Society (TOS)
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